TB Diagnostic Market Expected to Reach $3.1 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “TB Diagnostic Market," The tb diagnostic market was valued at $2.1 billion in 2022, and is estimated to reach $3.1 billion by 2032, growing at a CAGR of 4.1% from 2023 to 2032.

Tuberculosis (TB) is a bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs and also other parts of the body. A persistent cough that lasts more than three weeks is the most common symptom of tuberculosis. The BCG vaccination is given to protect individuals from TB infections. Based on the organ affected, the common types of tuberculosis include pulmonary tuberculosis, brain tuberculosis, and skeletal tuberculosis.

The key TB Diagnostic Market Trends such as rise in the number of cigarette smokers, large number of patients suffering from HIV infection, undernutrition, diabetes, and alcohol use disorders contribute to the growing prevalence of TB. Various studies have shown that smoking damages the lungs, making smokers more susceptible to TB infection. In addition, this increase in the prevalence of TB helps boost the demand for TB diagnostics. Similarly, the increase in R&D activities for the diagnostic tests of tb with maximum effectiveness of the test product augments the growth of the TB Diagnostic Industry. Moreover, the research activities are funded by private organizations or the government authorities for the study of infectious disease diagnostics. Hence, the growth in the expenditure from these authorities boosts the research activities that help in the increased use of TB diagnostic thereby driving the growth of the TB Diagnostic Market Size.

Moreover, launch of new products with advancement that fulfill the need of the hour and rise in the inclination toward R&D of the diagnostic tests that  are used to diagnose TB are projected to help boost the TB Diagnostic Industry growth in the coming years. Furthermore, the launch of new test products increases the options for choosing from the diagnostic test products for diagnosis of TB, which is expected to boost the market demand in the coming years. However, BCG vaccination, high cost of TB  diagnosis, ineffective healthcare infrastructure, stringent government regulations, and alternative diagnosis methods are expected to hinder the growth of the TB Diagnostic Market Size. Conversely, the technological advances in diagnosis, aging population in developed countries, and healthcare developments in emerging economies are expected to create lucrative opportunities for the market.

The TB diagnostic market is segmented on the basis of type, end user and region. On the basis of type, the market is categorized into culture-based diagnosis, sputum smear test, rapid molecular diagnosis and others. On the basis of end user, the market is classified into hospitals, diagnostic labs and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

On the basis of type, the market is classified into culture-based diagnosis, sputum smear test, rapid molecular diagnosis, and others. The rapid molecular diagnosis segment is projected to exhibit the fastest market growth during the forecast period, owing to an increase in the adoption of the rapid molecular diagnosis in the diagnosis of TB and the advancements in rapid molecular diagnosis. It tests for the presence of mycobacterium tuberculosis in the lungs. Furthermore, the World Health Organization (WHO) recommended rapid molecular diagnosis tests for diagnosis, thereby increasing the growth of the TB Diagnostic Market Share.

On the basis of end user, the market is classified into hospitals, diagnostic labs, and others. The diagnostic labs segment is anticipated to grow at the highest rate, owing to an upsurge in demand for TB diagnosis procedures. Moreover, an increase in the number of research for diagnostic tests of TB and rise in awareness regarding the use of advanced test products among the healthcare organizations contribute toward the growth of the TB Diagnostic Market Share.

On the basis of region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). In 2021, North America was the dominant region and is expected to remain dominant throughout the TB Diagnostic Market Forecast period, owing to technological advancements and development activities for diagnostics tests by the market players, increase in the number market players present in the region and surge in the product launches in the region. However, Asia-Pacific is expected to witness the highest CAGR during the TB Diagnostic Market Analysis period owing to an increase in the prevalence of TB infections. It helps to accelerate the demand for TB diagnostic products. Moreover, the adoption of strategies and trends such as product launch, product approval, partnership, collaboration, agreement, and acquisition by the market players boost the demand for TB diagnostics.

Key Findings of the Study

• By type, the rapid molecular diagnosis segment accounted for a major share of the TB diagnostic market in 2022.
• By end user, the hospitals segment is anticipated to grow with the highest CAGR throughout the forecast period.
• By region, North America occupied a major share of the TB diagnostic market in 2022